Drugs / DTaP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02062385 | May 2014 → Jun 2015 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02062385 ↗ |
| Modality | Vaccine | “Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care” NCT02062385 ↗ |
| Route | Intramuscular | “diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection” NCT02062385 ↗ |